Findings

What do systematic reviews say?

3,372 questions · 3,874 findings · 666 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 431 · 11.1%GRADE not reported 783 · 20.2%Very low 995 · 25.7%Low 909 · 23.5%Moderate 596 · 15.4%High 160 · 4.1%

ART sealant using high-viscosity glass ionomer (press-finger technique) vs Resin-based sealant

Development of carious lesions on sealed occlusal pits and fissures · Children with fully erupted permanent first molar teeth (mean age about 6 to 8 years)

At 48 months, no statistically significant difference was found between HVGIC and resin-based sealants (RR 0.62, 95% CI 0.31 to 1.21); evidence ungraded and at high risk of bias.

4 findings from 1 review

Caries-Preventive Effect of High-Viscosity Glass Ionomer and Resin-Based Fissure Sealants on Permanent Teeth: A… 2016 All outcomes
48 months · School- and clinic-based pediatric dental settings (Syria, Brazil, China, Turkey)
RR 0.62 [0.31, 1.21]
2 studies · 1007 evaluated sealed teeth participants
GRADE not reported
Caries-Preventive Effect of High-Viscosity Glass Ionomer and Resin-Based Fissure Sealants on Permanent Teeth: A… 2016 All outcomes
60 months · School- and clinic-based pediatric dental settings (Syria, Brazil, China, Turkey)
RR 0.29 [0.09, 0.95]
2 studies · 205 evaluated sealed teeth participants
GRADE not reported
Caries-Preventive Effect of High-Viscosity Glass Ionomer and Resin-Based Fissure Sealants on Permanent Teeth: A… 2016 All outcomes
36 months · School- and clinic-based pediatric dental settings (Syria, Brazil, China, Turkey)
RR 0.90 [0.49, 1.67]
3 studies · 600 evaluated sealed teeth participants
GRADE not reported

Show 1 more finding

Caries-Preventive Effect of High-Viscosity Glass Ionomer and Resin-Based Fissure Sealants on Permanent Teeth: A… 2016 All outcomes
24 months · School- and clinic-based pediatric dental settings (Syria, Brazil, China, Turkey)
RR 1.36 [0.66, 2.78]
4 studies · 1742 evaluated sealed teeth participants
GRADE not reported

High‐dose rhGH vs placebo

FEV1 % predicted: absolute change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

FVC (% predicted) Change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

Height velocity (cm/year) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

Change in weight (kg) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

QoL · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Very low

High‐dose rhGH vs placebo

Fasting blood glucose (mg/dL) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low

High‐dose rhGH vs placebo

Number of pulmonary exacerbations or hospitalisations · children and young adults with CF

High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with placebo (low certainty).

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
RR 1.92 [0.66, 5.61]
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

FEV1 % predicted: absolute change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

FVC (% predicted) Change from baseline · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

Height velocity (cm/year) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

Change in weight (kg) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

QoL · children and young adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐dose rhGH vs standard‐dose rhGH

Fasting blood glucose (mg/dL) · children and young adults with CF

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

High‐dose rhGH vs standard‐dose rhGH

Number of pulmonary exacerbations or hospitalisations · children and young adults with CF

High‐dose rhGH showed no clear difference in number of pulmonary exacerbations or hospitalisations compared with standard‐dose rhGH (low certainty).

1 finding from 1 review

Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
RR 1.28 [0.52, 3.18]
1 study · 42 participants
Low

High cell dose vs low cell dose

All‐cause mortality during hospital stay · people with critical limb ischaemia

1 finding from 1 review

Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
GRADE not reported

High cell dose vs low cell dose

Rate of amputation · people with critical limb ischaemia

It is very uncertain whether high cell dose changes amputation rate Assessed during in‐patient stay (Losordo 2012) compared with low cell dose (very low certainty).

1 finding from 1 review

Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical… 2018 · Cochrane Headline outcomes only
RR 3.21 [0.87, 11.9]
1 study · 16 participants
Very low

High cell dose vs low cell dose

Ulcer healing · people with critical limb ischaemia

The review found no eligible studies for this question.

1 finding from 1 review

Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High cell dose vs low cell dose

Rest‐pain relief · people with critical limb ischaemia

The review found no eligible studies for this question.

1 finding from 1 review

Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High cell dose vs low cell dose

Improvement in lower limb perfusion: ABI · people with critical limb ischaemia

The review found no eligible studies for this question.

1 finding from 1 review

Autologous cells derived from different sources and administered using different regimens for 'no‐option' critical… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found